State Street SPDR S&P Pharmaceuticals ETF (XPH) Stock Price, Quote, News & History

Edge Rankings

Stock Score Locked: Want to See it?

Benzinga Rankings give you vital metrics on any stock – anytime.

Reveal Full Score

Sector

Healthcare

Region

AUM

524.38M

Fund Score

Key Statistics

Open

$69.96

High

$71.00

52 Wk High

$71.13

AUM

524.38M

Dividend

$0.35

Ex-Div Date

Jun 22, 2026

Volume

131.17K

Market Cap

$38.46B

Mgmt Fee

0.35%

P/E Ratio

13.48

Prev. Close

$69.98

Low

$69.50

52 Wk Low

$44.60

Shares Out

4.85M

Yield

0.49%

Div. Freq

Avg. Volume Daily

111.94K

Beta

0.58

Avg. Expense Ratio

0.35%

P/B Ratio

3.01

Recent SPDR Series Trust News

Two Years to Build or Pay 200% — Which US Pharma Stocks Win?

Trump sets a 2-year ultimatum for generic drugmakers to reshore U.S. production or face tariffs up to 200%.

Stjepan Kalinic

Why Is Organon Stock Skyrocketing Monday?

Sun Pharma to acquire Organon in an all-cash deal valued at $11.75 billion. OGN shares rise on the acquisition news.

Akanksha Bakshi

Why Is Amneal Pharmaceuticals Stock Gaining Today?

Amneal Pharmaceuticals rises premarket after $1.1B Kashiv BioSciences deal to expand biosimilars platform and tap $300B biologics opportunity, while raising FY26 outlook.

Nabaparna Bhattacharya

Axsome Stock Climbs On Schizophrenia Drug Deal With Takeda

Axsome gains after securing global rights to balipodect from Takeda, advancing schizophrenia pipeline amid bullish analyst targets.

Vandana Singh

Prestige Bets $1 Billion On World's Most Iconic Nasal Strip

Prestige Consumer Healthcare acquires Breathe Right brand for $1.045 billion. Deal expands OTC portfolio into sleep & breathing categories.

Nabaparna Bhattacharya

FAQ

How do I buy State Street SPDR S&P Pharmaceuticals ETF (XPH) stock?

You can purchase shares of State Street SPDR S&P Pharmaceuticals ETF (ARCA:XPH) through any online brokerage.

View our list of the best stock brokerages

Who are State Street SPDR S&P Pharmaceuticals ETF (XPH) competitors?

There are no as such competitors for State Street SPDR S&P Pharmaceuticals ETF.

What is the forecast, or price target, for State Street SPDR S&P Pharmaceuticals ETF (XPH) stock?

There is no analysis for State Street SPDR S&P Pharmaceuticals ETF to provide a consensus price target.

What is the current price for State Street SPDR S&P Pharmaceuticals ETF (XPH)?

The stock price for State Street SPDR S&P Pharmaceuticals ETF (ARCA: XPH) is $ last updated .

Does State Street SPDR S&P Pharmaceuticals ETF (XPH) pay a dividend?

There are no upcoming dividends for State Street SPDR S&P Pharmaceuticals ETF.

When is State Street SPDR S&P Pharmaceuticals ETF (ARCA:XPH) reporting earnings?

State Street SPDR S&P Pharmaceuticals ETF does not have any upcoming earnings scheduled.

Is State Street SPDR S&P Pharmaceuticals ETF (XPH) going to split?

There is no upcoming split for State Street SPDR S&P Pharmaceuticals ETF.

Key Statistics

Open

$69.96

High

$71.00

52 Wk High

$71.13

AUM

524.38M

Dividend

$0.35

Ex-Div Date

Jun 22, 2026

Volume

131.17K

Market Cap

$38.46B

Mgmt Fee

0.35%

P/E Ratio

13.48

Prev. Close

$69.98

Low

$69.50

52 Wk Low

$44.60

Shares Out

4.85M

Yield

0.49%

Div. Freq

Avg. Volume Daily

111.94K

Beta

0.58

Avg. Expense Ratio

0.35%

P/B Ratio

3.01

About

Sector

N/A

Industry

N/A

ETF Details

Sector	Healthcare
Category	Mid Performer-Mid Growth
Investment Style	Mid Cap Blend
Fund Inception	Jun 19, 2006
Managers	Keith Richardson Karl A. Schneider
Definition	Most of the stocks in this equity fund have average financial performance and average growth potential

Investment Policy

In seeking to track the performance of the S&P Pharmaceuticals Select Industry Index (the index), the fund employs a sampling strategy. It generally invests substantially all, but at least 80%, of its total assets in the securities comprising the index. The index represents the pharmaceuticals segment of the S&P Total Market Index (S&P TMI).

Top ETF Holdings

Symbol	Name	Share %
CA	Definium Therapeutics,...	2.88%
ELVN	Enliven Therapeutics I...	2.04%
TRVI	Trevi Therapeutics Inc...	2.02%
MBX	Mbx Biosciences Inc	2.81%
ALMS	Alumis Inc Common Stoc...	2.05%
AMLX	Amylyx Pharmaceuticals...	2.01%
MAZE	Maze Therapeutics Inc	1.98%
MANE	Veradermics Inc	1.98%
ATAI	Ataibeckley Inc.	1.98%
LGND	Ligand Pharmaceuticals...	1.95%